Lunai Bioworks Inc. Common Stock (LNAI)
Stock · NASDAQ · Health Care
$0.68as of 10/16/2026
Price chart
Active signals
LNAI Signal Track Record
How signals performed across all stocks →What LNAI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 23 | -10.2% | 26% | September 24, 2026 |
| Volume Spike | 19 | -17.8% | 26% | September 23, 2026 |
| Bollinger Band Breakout | 16 | -15.9% | 19% | September 8, 2026 |
| Any 20-session window (baseline) | -11.2% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LNAI
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- renovarobio.com/
Fundamentals
- 1-day range
- $0.8757$1.68
- Market cap
- $10.97M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-7.63
- Dividend yield
- —
- Beta
- 0.31
- Avg. volume
- 193.2K
Lunai Bioworks Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LNAILunai Bioworks Inc. Common Stock$0.68▼ 17.68%Market cap $10.97MP/E —$0.8757$13.28
- BFRGBullfrog AI Holdings Inc. Common Stock$0.513▼ 4.11%Market cap $10.96MP/E —$0.4251$1.96
- KPRXKiora Pharmaceuticals Inc. Common Stock$2.4▼ 0.41%Market cap $11.35MP/E —$1.76$2.91
- TOVXTheriva Biologics Inc. Common Stock$0.21▲ 0.00%Market cap $10.32MP/E —$0.1628$0.8632
- ADILAdial Pharmaceuticals Inc Common Stock$3.49▲ 11.15%Market cap $10.29MP/E —$1.31$232.5
- BIVIBioVie Inc. Class A Common Stock$1.2▲ 6.19%Market cap $10.18MP/E —$0.82$3.79
- BLRXBioLineRx Ltd. American Depositary Shares$2.01▼ 1.95%Market cap $12.14MP/E Infinity$1.1$2.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LNAI Lunai Bioworks Inc. Common Stock | $10.97M | — | $0.68 | ▼ 17.68% | $0.8757$13.28 |
| BFRG Bullfrog AI Holdings Inc. Common Stock | $10.96M | — | $0.513 | ▼ 4.11% | $0.4251$1.96 |
| KPRX Kiora Pharmaceuticals Inc. Common Stock | $11.35M | — | $2.4 | ▼ 0.41% | $1.76$2.91 |
| TOVX Theriva Biologics Inc. Common Stock | $10.32M | — | $0.21 | ▲ 0.00% | $0.1628$0.8632 |
| ADIL Adial Pharmaceuticals Inc Common Stock | $10.29M | — | $3.49 | ▲ 11.15% | $1.31$232.5 |
| BIVI BioVie Inc. Class A Common Stock | $10.18M | — | $1.2 | ▲ 6.19% | $0.82$3.79 |
| BLRX BioLineRx Ltd. American Depositary Shares | $12.14M | Infinity | $2.01 | ▼ 1.95% | $1.1$2.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Lunai Bioworks Requests Immediate Nasdaq Trading Suspension Amid Allegations Of Short Selling And Failures To DeliverBenzinga · 10/9/2026
- Stock Market: Will S&P 500 Open Up or Down Today?Benzinga · 10/2/2026
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga · 10/1/2026
- Lunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2MBenzinga · 9/29/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/28/2026
- Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist AgreementYahoo · 9/22/2026
- Lunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation PlatformBenzinga · 9/22/2026
- Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AIYahoo · 9/16/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Lunai Bioworks Files Non‑Timely 10‑K, Projects $3.2M Net Loss
Lunai Bioworks reported that it will file its 10‑K with the SEC after the deadline. The company expects a net loss of roughly $3.2 million for the fiscal year ending June 30, 2026. This filing highlights ongoing financial challenges for the biotech firm.
Lunai Bioworks Files Non‑Timely 10‑K, Projects $3.2M Net Loss. Lunai Bioworks reported that it will file its 10‑K with the SEC after the deadline. The company expects a net loss of roughly $3.2 million for the fiscal year ending June 30, 2026. This filing highlights ongoing financial challenges for the biotech firm.